Compare Crispr Therapeutics AG (CRSP) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs BlackRock TCP Capital Corp — how do they compare? Crispr Therapeutics AG trades at $53.59 (market cap $4.88B), while BlackRock TCP Capital Corp trades at $4.04 (market cap $337.71M). The key difference: Crispr Therapeutics AG is far larger — about 14.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TCPC | |
|---|---|---|
Market Cap | $4.88B | $337.71M |
Volume | 2,861,747 | 436,109 |
Sector | Health | Financials |
52-Week High | $74.92 | $6.20 |
52-Week Low | $44.34 | $3.13 |
Typical Hold Time | 77 Days | — |
Enterprise Value | $3.30B | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
TCPC trades at $4.01, up 1.78% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.22 per share, beating expectations, and announced a $523 million portfolio sale to reduce leverage. However, revenue and net income remain negative, with a net income margin of 118.75% in 2026 indicating significant losses relative to revenue. The stock is trading below book value with a P/B of 0.61.
The outlook is mixed: strategic actions like portfolio sales may improve financial health, but persistent negative earnings and a class action lawsuit pose risks. Analyst sentiment is cautious with a 30.77% buy rating. Investors should weigh the potential for operational turnaround against ongoing profitability challenges and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
